Webcast ready to view
Recorded May 27, 2021
Hypoglycemia can present differently from person to person and therefore an individualized approach is imperative to manage each patient’s symptoms and risk factors. With the increasing number of treatment and management options becoming available, deciding on the best course of action can be more difficult.
This interactive CME-accredited webcast aims to support you to make these decisions.
Watch experts in a lively debate presenting real-life patient cases, and discussing where newer therapies can be best utilized.
This program is suitable for, but not limited to, endocrinologists, diabetologists, and primary care practitioners.
The onDemand webcast is available in English, French, German, Italian, and Spanish.
Faculty and disclosures
Program director and webinar chair
Professor of Clinical Diabetes, University of Sheffield, Sheffield, UK
Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.
He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA. He was Editor of Diabetic Medicine from 2000-2005. He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee.
He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia. The group has a remit to reduce the burden of hypoglycemia though educational activities.
He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.
His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia. He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management. He has authored over 200 original research articles and reviews.
Advisory Board Member: Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG, Boehringer Ingelheim. Consultant: Eli Lilly, Novo Nordisk. Speaker’s Bureau: Eli Lilly, Novo Nordisk.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.